A Vivus shareholder who wants to stack the drugmaker's board with a more aggressive slate of directors has brought in one of the champions of this kind of shareholder brawl. Alex Denner, who gained his experience in proxy fights as the head of Carl Icahn's?healthcare investments, has been invited to the battle by investor First Manhattan Co.
Read the rest here:
Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board
Having failed so far to get its extended-release?Parkinson's?drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do.
Original post:
Impax calls on former Teva, Watson execs to confront FDA issues
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Here is the original post:
Does pharma spend more on marketing than R&D? A numbers check
According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab to his government contacts–at a time when he also served on the company's board.
More here:
Ex-HGS director draws fire for plugging anthrax drug at Pentagon
According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab to his government contacts–at a time when he also served on the company's board.
See original here:
Ex-HGS director draws fire for plugging anthrax drug at Pentagon
Forty-five women who had turned to Apotex for contraceptives to avoid having children are now looking to the Canadian drugmaker to help them pay for their babies, or their abortions, after they ended up pregnant.
View original post here:
Women want Apotex to pay for unwanted pregnancies
Forty-five women who had turned to Apotex for contraceptives to avoid having children are now looking to the Canadian drugmaker to help them pay for their babies, or their abortions, after they ended up pregnant.
Read the original post:
Women want Apotex to pay for unwanted pregnancies
New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.
Read this article:
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.
Read more from the original source:
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
| © 2011 MSL WORLD |